P2-163: Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC): A Single Institution Canadian Experience  by Banerji, Shantanu et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS634
Results: A total of 28 patients were enrolled on this study from four 
institutions between 15/7/02 and 11/7/05. Patient characteristics: me-
dian age 65 (range 50 - 75). Male 61%. Performance status 0/1:11/17. 
Histology: squamous/mixed 12, adenocarcinoma 6, large cell/undif-
ferentiated 10. Stage IIA 1, IIIA 16, IIIB 11. All patients received 60Gy. 
Chemotherapy dose was successfully escalated to level 4 (expanded 
cohort: 16 patients). No DLT’s were observed during the escalation 
phase. Response (28 patients evaluable): overall response rate 61% on 
PET scan, 46% on CT; complete response 43% (PET) 21% (CT). Of 16 
patients failing, ﬁrst site of progression was locoregional: 11, distant: 
4 and both: 1. At the close-out date 31/10/06 median survival had not 
been reached and survival at 24 months was 60% (95% CI: 39-82%).
Conclusions: Geﬁtinib 250mg per day can be safely given with full 
dose chemoradiation consisting of 60Gy plus carboplatin and paclitax-
el. Locoregional progression is the major cause of treatment failure.
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Background: Combined modality therapy remains the best chance of 
cure in the setting of locally advanced NSCLC. The optimal combina-
tion of concurrent chemotherapy and radiation (CRT) continues to 
evolve. In this study we report our single institution experience with 
tri-modality therapy in patients with Stage III NSCLC.
Methods: 55 patients with Stage III NSCLC and ECOG 0-1 were 
prospectively studied between September 1995 and March 2004 at 
CancerCare Manitoba, Winnipeg, Canada. From 1995 through 1997, 
the standard regimen (PE) consisted of Cisplatin (25 mg/m2) & Eto-
poside (100 mg/m2) for 3 days every 3 weeks for 2 cycles combined 
with either radical intent (5000 cGy in 20 fractions) or palliative intent 
(3000-3500 cGy in 10 fractions) concurrent radiation. In 1998, the stan-
dard regimen was switched to TC using Carboplatin (AUC 3) & Pacli-
taxel (45mg/m2) once weekly for 4-6 weeks combined with 5000 cGy 
in 20 fractions. After a treatment related death in 1999, the Carboplatin 
dose was reduced (AUC 2) and radiation was revised to either 4500 
cGy in 25 fractions for Stage IIIa or 6000 cGy in 30 fractions for Stage 
IIIb disease. All patients were assessed for clinical response, toxicity, 
surgical resection, pathologic response, and survival.
Results: Median age was 62, Stage IIIa 59%, and Adenocarcinoma 
43%. Eighty-eight percent of patients received their prescribed dose of 
PE and 90% received at least four cycles of prescribed TC chemothera-
py. Radical radiation therapy was the intended therapy in 95% of cases 
however only 75% of patients received at least 5000 cGy of radiation. 
Clinical response to therapy is shown in the table below.
Regimen N
Complete 
Response
Partial 
Response
Stable 
Disease
Progressive 
Disease
Cisplatin & Etoposide (PE) 26 0 (0%) 17 (59%) 8 (28%) 4 (14%)
Carboplatin & Paclitaxel (TC) 29 2 (8%) 8 (31%) 8 (31%) 8 (31%)
Grade 3 toxicity occurred in 2 patients on PE and 10 on TC. One 
patient receiving TC died of treatment related toxicity. Ten patients in 
each chemotherapy group went on to surgical resection with partial 
pathologic response seen in 50% PE and 80% TC. Median survival 
was 2.05 years for this population with no signiﬁcant survival differ-
ence between treatment groups (PE 2.25 vs. TC 1.98 years, p = 0.39). 
Dose of radiation (≥5000 cGy vs. <5000 cGy) did not signiﬁcantly 
impact survival. Patients who proceeded to surgical resection survived 
a median of 3.33 years compared to 1.62 years for un-resected patients 
(p = 0.0006).
Conclusions: In our experience, both combinations of chemotherapy 
combined with radiation were equally effective in terms of overall sur-
vival in Stage III NSCLC. TC based CRT appears to have better clini-
cal and pathologic response compared to PE at the expense of a slight 
increase in treatment related toxicity. The few patients who proceeded 
to surgery post CRT had signiﬁcantly improved survival.
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Background: Purpose of this study was to evaluate feasibility of 
thoracic radiotherapy (TRT) with concurrent daily low-dose carboplatin 
for inoperable stage III NSCLC in elderly or frail patients in the Central 
European population. 
Methods: Modiﬁed Japanese treatment protocol originally published 
by Atagi et al (Jpn J Clin Oncol, 30, 2, 59-64) was used. TRT 60 Gy (2 
Gy fractions, 5 days a week) was administered over a 6-week period. 
Carboplatin 25 mg/m2 as a 30 min infusion was given one hour before 
TRT, daily, over four weeks, starting on day one. The eligibility criteria 
for patients included: age 65 years or over with ECOG PS 0 - 2 or 
younger with ECOG PS 2, histologically and/or cytologically con-
ﬁrmed NSCLC, inoperable stage III disease, satisfactory blood count 
and standard biochemical parameters. There was no age-limit. 
Results: Twenty patients were treated. Patients´ characteristics: elderly/
non-elderly: 18/2, age - median: 73.5 years (range: 55 - 80), male/fe-
male: 18/2, ECOG PS 0/1/2: 0/10/10, squamous cell carcinoma/adeno-
carcinoma: 18/2. All patients were assessable for treatment response 
and toxicity. In fourteen was it possible to administer the entire proto-
col therapy without any disruption. The response by the end of treat-
ment was: complete response: 0, partial response: 12 (60%; 95%CI: 39 
- 78%), stable disease: 7 (35%; 95%CI: 18 - 57%), progressive disease: 
1 (5%; 95%CI: 1 - 24%). Survival time - median: 19 months (range: 3 
- 36+; 95%CI: 10 - 26), 2-year survival rate - 35% (95%CI: 18 - 57%). 
Main toxicities were as follows: NCI CTC grade 3/4 neutropenia in 
25/5%, thrombocytopenia in 15/5%, febrile neutropenia in 5/0%, respi-
ratory infection in 10/0%, and esophagitis in 5/0%. Transfusions and/or 
erythropoietin were given due to grade 2 anemia in 40% of patients. All 
toxicities were manageable and there was no treatment related death.
Conclusion: TRT with daily low-dose carboplatin was feasible in our 
group of patients. Response rates and survival are comparable with 
those achieved in younger good prognosis patients by more sophisti-
cated combinations of TRT and chemotherapy. 
